免疫导向分子影像生物标志物
本文综述肿瘤靶向治疗与免疫治疗时代传统影像的局限,指出FDG-PET在免疫治疗评估中的不足,强调对药效学和预后影像生物标志物的迫切需求。放射性标记抗体或小分子可特异性评估靶点表达与浓度,针对EGFR通路的早期人体研究显示潜力,CA19.9与CA-IX靶向成像正在探索,免疫导向显像剂作为生物标志物前景可期,但仍需更大规模设计良好的研究验证其临床管理价值。
要点
- FDG-PET对免疫治疗评估存在局限,亟需药效学与预后影像生物标志物。
- 放射性标记抗体或小分子可特异性评估靶点表达与浓度。
- 免疫导向显像剂作为生物标志物仍需大规模研究验证。
核心结论
- 免疫导向分子影像生物标志物具有临床潜力,但需更大规模设计良好的研究验证其在患者临床管理中的作用。
研究设计与样本
- 本文为综述,汇总放射性标记抗体与小分子用于靶向及免疫导向分子影像的临床前开发与早期人体研究。
主要发现
- 针对表皮生长因子受体通路的放射性标记单克隆抗体或小分子早期人体研究显示潜力。
- CA19.9与CA-IX的靶向成像正在进一步探索。
- 靶向免疫机制的放射性标记抗体初步研究看起来有前景。
临床怎么用
- 在免疫治疗与靶向治疗中,可关注免疫导向分子影像作为药效学与预后生物标志物的潜在补充价值。
局限性
- 新型显像剂仍在开发中,作为临床管理生物标志物的作用尚缺乏大规模设计良好的研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging has played a critical role in the management of patients with cancer. Novel therapies are emerging rapidly; however, they are effective only in some patients. With the advent of new targeted therapeutics and immunotherapy, the limitations of conventional imaging methods are becoming more evident. FDG-PET imaging is restricted to the optimal assessment of immune therapies. There is a critical unmet need for pharmacodynamic and prognostic imaging biomarkers. Radiolabeled antibodies or small molecules can allow for specific assessment of targets in expression and concentration. Several such imaging agents have been under preclinical development. Early human studies with radiolabeled monoclonal antibodies or small molecules targeted to the epidermal growth factor receptor pathway have shown potential; targeted imaging of CA19.9 and CA-IX and are being further explored. Immune-directed imaging agents are highly desirable as biomarkers and preliminary studies with radiolabeled antibodies targeting immune mechanisms appear promising. While novel agents are being developed, larger well-designed studies are needed to validate the role of these agents as biomarkers in the clinical management of patients.
引用
- Pandit-Taskar N, Postow MA. Immune-Directed Molecular Imaging Biomarkers. Semin Nucl Med. 2020. PMID: 33059826. doi:10.1053/j.semnuclmed.2020.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。